ABL-105 is under clinical development by ABL Bio and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABL-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABL-105 overview
ABL-105 is under development for the treatment of solid tumor including human epidermal growth factor receptor 2 positive breast cancer (her2 positive breast cancer), gastric cancer, gastroesophageal junction carcinomas and biliary tract cancer. The drug candidate is a bi-specific monoclonal antibody. It acts by targeting cells expressing Her2 and Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB). The drug candidate is developed as T cell engager based on Grabody T BsAb Platform.
ABL Bio overview
ABL Bio is a biotechnology company that develops bispecific antibodies for immuno-oncology and neurodegenerative diseases. It utilizes Grabody -T, Grabody -I and Grabody -B technology platforms to develop drugs. ABL Bio’s pipeline products include ABL101, ABL301, ABL503, ABL111, ABL102, ABL103, ABL104, ABL105, ABL602 and ABL501. Its pipeline products treat Parkinson’s disease, biliary tract cancer, colorectal cancer, oral verrucous carcinoma, solid tumors, solid and blood tumors, breast cancer, gastric cancer, solid cancer and blood cancer. ABL Bio is headquartered in Seongnam-Si, South Korea.
For a complete picture of ABL-105’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
